Virginie Dufrost1, Jessie Risse1,2, Stéphane Zuily3,4, Denis Wahl1,2. 1. CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France. 2. Inserm UMR_S 1116 at Lorraine University, Nancy, France. 3. CHRU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France. s.zuily@chru-nancy.fr. 4. Inserm UMR_S 1116 at Lorraine University, Nancy, France. s.zuily@chru-nancy.fr.
Abstract
BACKGROUND: The cornerstone of thrombotic antiphospholipid syndrome (APS) patients' management is to prevent recurrent thrombosis by long-term anticoagulation. PURPOSE OF REVIEW: The purpose of the review is to summarize available literature on direct oral anticoagulants (DOACs) use in APS patients through a systematic review and to determine factors associated with thrombosis recurrence. RECENT FINDINGS: The recent RAPS trial demonstrated that APS patients treated with rivaroxaban had a significant twofold-increased thrombin potential, suggesting a higher thrombotic risk, in comparison with warfarin users. Furthermore, several reports of APS patients treated with DOACs have raised safety issues. Our systematic review identified 122 published APS patients treated with DOACs; among them, 19 experienced a recurrent thrombosis while on DOACs. Of note, triple positivity (positivity of all three laboratory criteria for APS) was associated with a 3.5-fold increased risk for recurrent thrombosis. In conclusion, DOACs should be used with caution in APS patients and randomized control trials with clinical primary endpoints assessing clinical efficacy and safety are awaited to establish whether the prescription of DOACs could be a safe alternative to warfarin.
BACKGROUND: The cornerstone of thrombotic antiphospholipid syndrome (APS) patients' management is to prevent recurrent thrombosis by long-term anticoagulation. PURPOSE OF REVIEW: The purpose of the review is to summarize available literature on direct oral anticoagulants (DOACs) use in APSpatients through a systematic review and to determine factors associated with thrombosis recurrence. RECENT FINDINGS: The recent RAPS trial demonstrated that APSpatients treated with rivaroxaban had a significant twofold-increased thrombin potential, suggesting a higher thrombotic risk, in comparison with warfarin users. Furthermore, several reports of APSpatients treated with DOACs have raised safety issues. Our systematic review identified 122 published APSpatients treated with DOACs; among them, 19 experienced a recurrent thrombosis while on DOACs. Of note, triple positivity (positivity of all three laboratory criteria for APS) was associated with a 3.5-fold increased risk for recurrent thrombosis. In conclusion, DOACs should be used with caution in APSpatients and randomized control trials with clinical primary endpoints assessing clinical efficacy and safety are awaited to establish whether the prescription of DOACs could be a safe alternative to warfarin.
Authors: Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: D R J Arachchillage; I J Mackie; M Efthymiou; A Chitolie; B J Hunt; D A Isenberg; M Khamashta; S J Machin; H Cohen Journal: J Thromb Haemost Date: 2016-09-30 Impact factor: 5.824
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245